Your browser doesn't support javascript.
loading
Enhanced Maturation of 3D Bioprinted Skeletal Muscle Tissue Constructs Encapsulating Soluble Factor-Releasing Microparticles.
de Barros, Natan Roberto; Darabi, Mohammad Ali; Ma, Xin; Diltemiz, Sibel Emir; Ermis, Menekse; Hassani Najafabadi, Alireza; Nadine, Sara; Banton, Ethan A; Mandal, Kalpana; Abbasgholizadeh, Reza; Falcone, Natashya; Mano, João F; Nasiri, Rohollah; Herculano, Rondinelli Donizetti; Zhu, Yangzhi; Ostrovidov, Serge; Lee, Junmin; Kim, Han-Jun; Hosseini, Vahid; Dokmeci, Mehmet R; Ahadian, Samad; Khademhosseini, Ali.
Afiliação
  • de Barros NR; Terasaki Institute for Biomedical Innovation (TIBI), Los Angeles, CA, 90064, USA.
  • Darabi MA; Terasaki Institute for Biomedical Innovation (TIBI), Los Angeles, CA, 90064, USA.
  • Ma X; Center for Minimally Invasive Therapeutics (C-MIT), University of California-Los Angeles, Los Angeles, CA, 90095, USA.
  • Diltemiz SE; Department of Chemistry, Eskisehir Technical University, Eskisehir, 26470, Turkey.
  • Ermis M; Terasaki Institute for Biomedical Innovation (TIBI), Los Angeles, CA, 90064, USA.
  • Hassani Najafabadi A; Terasaki Institute for Biomedical Innovation (TIBI), Los Angeles, CA, 90064, USA.
  • Nadine S; Terasaki Institute for Biomedical Innovation (TIBI), Los Angeles, CA, 90064, USA.
  • Banton EA; CICECO - Aveiro Institute of Materials, Department of Chemistry, University of Aveiro, Campus Universitário de Santiago, Aveiro, 3810-193, Portugal.
  • Mandal K; Center for Minimally Invasive Therapeutics (C-MIT), University of California-Los Angeles, Los Angeles, CA, 90095, USA.
  • Abbasgholizadeh R; Terasaki Institute for Biomedical Innovation (TIBI), Los Angeles, CA, 90064, USA.
  • Falcone N; Terasaki Institute for Biomedical Innovation (TIBI), Los Angeles, CA, 90064, USA.
  • Mano JF; Terasaki Institute for Biomedical Innovation (TIBI), Los Angeles, CA, 90064, USA.
  • Nasiri R; CICECO - Aveiro Institute of Materials, Department of Chemistry, University of Aveiro, Campus Universitário de Santiago, Aveiro, 3810-193, Portugal.
  • Herculano RD; Terasaki Institute for Biomedical Innovation (TIBI), Los Angeles, CA, 90064, USA.
  • Zhu Y; Terasaki Institute for Biomedical Innovation (TIBI), Los Angeles, CA, 90064, USA.
  • Ostrovidov S; Terasaki Institute for Biomedical Innovation (TIBI), Los Angeles, CA, 90064, USA.
  • Lee J; Department of Radiological Sciences, University of California-Los Angeles, Los Angeles, CA, 90095, USA.
  • Kim HJ; Terasaki Institute for Biomedical Innovation (TIBI), Los Angeles, CA, 90064, USA.
  • Hosseini V; Department of Materials Science and Engineering, Pohang University of Science and Technology (POSTECH), Pohang, 790-784, Republic of Korea.
  • Dokmeci MR; Terasaki Institute for Biomedical Innovation (TIBI), Los Angeles, CA, 90064, USA.
  • Ahadian S; College of Pharmacy, Korea University, Sejong, 30019, Republic of Korea.
  • Khademhosseini A; Vellore Institute of Technology (VIT), Vellore, 632014, India.
Macromol Biosci ; 23(12): e2300276, 2023 Dec.
Article em En | MEDLINE | ID: mdl-37534566
Several microfabrication technologies have been used to engineer native-like skeletal muscle tissues. However, the successful development of muscle remains a significant challenge in the tissue engineering field. Muscle tissue engineering aims to combine muscle precursor cells aligned within a highly organized 3D structure and biological factors crucial to support cell differentiation and maturation into functional myotubes and myofibers. In this study, the use of 3D bioprinting is proposed for the fabrication of muscle tissues using gelatin methacryloyl (GelMA) incorporating sustained insulin-like growth factor-1 (IGF-1)-releasing microparticles and myoblast cells. This study hypothesizes that functional and mature myotubes will be obtained more efficiently using a bioink that can release IGF-1 sustainably for in vitro muscle engineering. Synthesized microfluidic-assisted polymeric microparticles demonstrate successful adsorption of IGF-1 and sustained release of IGF-1 at physiological pH for at least 21 days. Incorporating the IGF-1-releasing microparticles in the GelMA bioink assisted in promoting the alignment of myoblasts and differentiation into myotubes. Furthermore, the myotubes show spontaneous contraction in the muscle constructs bioprinted with IGF-1-releasing bioink. The proposed bioprinting strategy aims to improve the development of new therapies applied to the regeneration and maturation of muscle tissues.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Alicerces Teciduais / Bioimpressão Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Alicerces Teciduais / Bioimpressão Idioma: En Ano de publicação: 2023 Tipo de documento: Article